Gastrointestinal stromal tumors: pathology and prognosis at different sites.

By M. Miettinen, J. Lasota. Seminars in diagnostic pathology, 2006

2,001 citations recorded by the source corpus.

Subfields: Gastroenterology, Neurology, Surgery

View Paper: https://www.semanticscholar.org/paper/e4152831060f0ec60abc4facfea151bd5d1f4869

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Gastroenterology

1. Heikki Joensuu

In Neurology

1. Heikki Joensuu

In Surgery

1. Heikki Joensuu

Citations in the corpus

• One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. (2012, methodology): “The GIST was required to be histologically diagnosed, to be KIT (CD117) positive in immunostaining, and to have a high estimated risk of recurrence according to the modified National Institutes of Health (NIH) Consensus Criteria with at least 1 of the following features: (1) the longest tumor diamet”
• Risk stratification of patients diagnosed with gastrointestinal stromal tumor. (2008, background): “Other AFIP series of GISTs located in the duodenum and rectum further illustrate the importance of tumor site in risk stratification [34].”